Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VCNX | US
-0.08
-3.08%
Healthcare
Biotechnology
01/01/1970
17/10/2024
2.52
2.57
2.68
2.42
Vaccinex Inc. a clinical-stage biotechnology company engages in the discovery and development of targeted biotherapeutics to treat cancer neurodegenerative diseases and autoimmune disorders. The company's lead drug candidate pepinemab a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb an antibody drug discovery platform based on a novel method for complex targets such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester New York.
View LessHigh Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
198.5%1 month
160.5%3 months
147.4%6 months
126.2%-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.00
Range1M
4.61
Range3M
7.51
Rel. volume
0.49
Price X volume
120.53K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.735 | 0 | -3.37% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 64.615 | 0 | -1.88% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2228 | 0 | -0.45% | n/a | |
VINC | VINC | Biotechnology | 0.3775 | 0 | -5.15% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.99 | 0 | 3.37% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.46 | 0 | -2.50% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 39.89 | 0 | -0.25% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.31 | 0 | -1.18% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 40.67 | 0 | -1.45% | n/a | |
Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.002 | 0 | 0.00% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 147.40 | 72.92 | Riskier |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | - | 3.78B | - |